Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 215

1.

RISK FACTORS FOR HEARING IMPAIRMENT IN TYPE 1 DIABETES.

Braffett BH, Lorenzi GM, Cowie CC, Gao X, Bainbridge KE, Cruickshanks KJ, Kramer JR, Gubitosi-Klug RA, Larkin ME, Barnie A, Lachin JM, Schade DS; DCCT/EDIC Research Group.

Endocr Pract. 2019 Aug 14. doi: 10.4158/EP-2019-0193. [Epub ahead of print]

PMID:
31412233
2.

Author Correction: Differentiation of cardiomyocytes and generation of human engineered heart tissue.

Breckwoldt K, Brenière-Letuffe D, Mannhardt I, Schulze T, Ulmer B, Werner T, Benzin A, Klampe B, Reinsch MC, Laufer S, Shibamiya A, Prondzynski M, Mearini G, Schade D, Fuchs S, Neuber C, Krämer E, Saleem U, Schulze ML, Rodriguez ML, Eschenhagen T, Hansen A.

Nat Protoc. 2019 Sep;14(9):2748. doi: 10.1038/s41596-019-0228-5.

PMID:
31384055
3.

Should Routine Screening for Coronary Artery Disease Be Recommended? A Comparison With Routine Screening for Colon Cancer.

Schade DS, Arora S, Eaton RP.

Am J Med. 2019 Jul 10. pii: S0002-9343(19)30567-4. doi: 10.1016/j.amjmed.2019.06.032. [Epub ahead of print] No abstract available.

PMID:
31301292
4.

A Feasible, Simple, Cost-Saving Program to End Cardiovascular Disease in the United States.

Schade DS, Obenshain SS, Ramo B, Eaton RP.

Am J Med. 2019 Apr 15. pii: S0002-9343(19)30328-6. doi: 10.1016/j.amjmed.2019.03.043. [Epub ahead of print] No abstract available.

PMID:
30998922
5.

Prevention of Statin Overtreatment and Increased Patient Compliance in High-Cardiovascular-Risk Individuals.

Schade DS, Obenshain SS, Eaton RP.

Am J Med. 2019 Apr 4. pii: S0002-9343(19)30279-7. doi: 10.1016/j.amjmed.2019.03.020. [Epub ahead of print] No abstract available.

PMID:
30953634
6.

Unique photoaffinity probes to study TGFβ signaling and receptor fates.

Längle D, Wesseler F, Flötgen D, Leek H, Plowright AT, Schade D.

Chem Commun (Camb). 2019 Apr 9;55(30):4323-4326. doi: 10.1039/c9cc00929a.

PMID:
30887988
7.

The Association of Coronary Artery Calcification With Subsequent Incidence of Cardiovascular Disease in Type 1 Diabetes: The DCCT/EDIC Trials.

Budoff M, Backlund JC, Bluemke DA, Polak J, Bebu I, Schade D, Strowig S, Raskin P, Lachin JM; DCCT/EDIC Research Group.

JACC Cardiovasc Imaging. 2019 Jul;12(7 Pt 2):1341-1349. doi: 10.1016/j.jcmg.2019.01.014. Epub 2019 Mar 13.

PMID:
30878435
8.

Prescribing Statins to Reduce Cardiovascular Disease: 10 Common Misconceptions.

Schade DS, Shey L, Eaton RP.

Am J Med. 2019 Aug;132(8):897-899. doi: 10.1016/j.amjmed.2019.01.042. Epub 2019 Mar 6. No abstract available.

PMID:
30851261
9.

Tetrahydroindoles as Multipurpose Screening Compounds and Novel Sirtuin Inhibitors.

Vojacek S, Schulig L, Wössner N, Geist N, Langel W, Jung M, Schade D, Link A.

ChemMedChem. 2019 Apr 17;14(8):853-864. doi: 10.1002/cmdc.201900054. Epub 2019 Mar 21.

PMID:
30811852
10.

A Simplified Approach to Reducing Cardiovascular Risk.

Schade DS, Eaton RP.

J Clin Endocrinol Metab. 2019 Feb 20. pii: jc.2018-02509. doi: 10.1210/jc.2018-02509. [Epub ahead of print]

PMID:
30785997
11.

Toward Second-Generation Cardiomyogenic and Anti-cardiofibrotic 1,4-Dihydropyridine-Class TGFβ Inhibitors.

Längle D, Werner TR, Wesseler F, Reckzeh E, Schaumann N, Drowley L, Polla M, Plowright AT, Hirt MN, Eschenhagen T, Schade D.

ChemMedChem. 2019 Apr 17;14(8):810-822. doi: 10.1002/cmdc.201900036. Epub 2019 Feb 28.

PMID:
30768867
12.

Hearing Impairment and Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Cohort.

Schade DS, Lorenzi GM, Braffett BH, Gao X, Bainbridge KE, Barnie A, Cruickshanks KJ, Dalton D, Diminick L, Gubitosi-Klug R, Kramer JR, Lachin JM, Larkin ME, Cowie CC; DCCT/EDIC Research Group.

Diabetes Care. 2018 Dec;41(12):2495-2501. doi: 10.2337/dc18-0625. Epub 2018 Sep 25.

PMID:
30254082
13.

Combined Proteomic and In Silico Target Identification Reveal a Role for 5-Lipoxygenase in Developmental Signaling Pathways.

Brand S, Roy S, Schröder P, Rathmer B, Roos J, Kapoor S, Patil S, Pommerenke C, Maier T, Janning P, Eberth S, Steinhilber D, Schade D, Schneider G, Kumar K, Ziegler S, Waldmann H.

Cell Chem Biol. 2018 Sep 20;25(9):1095-1106.e23. doi: 10.1016/j.chembiol.2018.05.016. Epub 2018 Jun 28.

PMID:
30251630
14.

Discovery of Inhibitor of Wnt Production 2 (IWP-2) and Related Compounds As Selective ATP-Competitive Inhibitors of Casein Kinase 1 (CK1) δ/ε.

García-Reyes B, Witt L, Jansen B, Karasu E, Gehring T, Leban J, Henne-Bruns D, Pichlo C, Brunstein E, Baumann U, Wesseler F, Rathmer B, Schade D, Peifer C, Knippschild U.

J Med Chem. 2018 May 10;61(9):4087-4102. doi: 10.1021/acs.jmedchem.8b00095. Epub 2018 May 1.

PMID:
29630366
15.

Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D.

Basu A, Jenkins AJ, Stoner JA, Zhang Y, Klein RL, Lopes-Virella MF, Garvey WT, Schade DS, Wood J, Alaupovic P, Lyons TJ; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.

J Lipid Res. 2018 May;59(5):872-883. doi: 10.1194/jlr.P080143. Epub 2018 Mar 25.

16.

Management of Asymptomatic Patients With Positive Coronary Artery Calcium Scans.

Burge MR, Eaton RP, Comerci G, Cavanaugh B, Ramo B, Schade DS.

J Endocr Soc. 2017 Jun 1;1(6):588-599. doi: 10.1210/js.2016-1080. eCollection 2017 Jun 1. Review.

17.

THE TIMING OF MEAL INSULIN ADMINISTRATION.

Schade DS.

Endocr Pract. 2017 Dec;23(12):1482-1484. doi: 10.4158/EP-2017-0073. Epub 2017 Nov 16. No abstract available.

PMID:
29144810
18.

Cell Permeable Stapled Peptide Inhibitor of Wnt Signaling that Targets β-Catenin Protein-Protein Interactions.

Dietrich L, Rathmer B, Ewan K, Bange T, Heinrichs S, Dale TC, Schade D, Grossmann TN.

Cell Chem Biol. 2017 Aug 17;24(8):958-968.e5. doi: 10.1016/j.chembiol.2017.06.013. Epub 2017 Jul 27.

19.

Differentiation of cardiomyocytes and generation of human engineered heart tissue.

Breckwoldt K, Letuffe-Brenière D, Mannhardt I, Schulze T, Ulmer B, Werner T, Benzin A, Klampe B, Reinsch MC, Laufer S, Shibamiya A, Prondzynski M, Mearini G, Schade D, Fuchs S, Neuber C, Krämer E, Saleem U, Schulze ML, Rodriguez ML, Eschenhagen T, Hansen A.

Nat Protoc. 2017 Jun;12(6):1177-1197. doi: 10.1038/nprot.2017.033. Epub 2017 May 11. Erratum in: Nat Protoc. 2019 Sep;14(9):2748.

PMID:
28492526
20.

Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium.

Goldberg RB, Aroda VR, Bluemke DA, Barrett-Connor E, Budoff M, Crandall JP, Dabelea D, Horton ES, Mather KJ, Orchard TJ, Schade D, Watson K, Temprosa M; Diabetes Prevention Program Research Group.

Circulation. 2017 Jul 4;136(1):52-64. doi: 10.1161/CIRCULATIONAHA.116.025483. Epub 2017 May 5.

21.

INSULIN TIMING: A PATIENT-CENTERED APPROACH TO IMPROVE CONTROL IN TYPE 1 DIABETES.

Duran-Valdez E, Burge MR, Broderick P, Shey L, Valentine V, Schrader RM, Schade DS.

Endocr Pract. 2017 Apr 2;23(4):471-478. doi: 10.4158/EP161265.OR. Epub 2017 Feb 3.

PMID:
28156154
22.

Abnormal Coronary Artery Calcium Scans in Asymptomatic Patients.

Eaton RP, Burge MR, Comerci G, Cavanaugh B, Ramo B, Schade DS.

Am J Med. 2017 Apr;130(4):394-397. doi: 10.1016/j.amjmed.2016.10.006. Epub 2016 Nov 1. No abstract available.

PMID:
27810478
23.

Platform for determining the inhibition profile of neuraminidase inhibitors in an influenza virus N1 background.

Hoffmann A, Schade D, Kirchmair J, Clement B, Sauerbrei A, Schmidtke M.

J Virol Methods. 2016 Nov;237:192-199. doi: 10.1016/j.jviromet.2016.09.014. Epub 2016 Sep 19.

PMID:
27659246
24.

The Role of a Coronary Artery Calcium Scan in Type 1 Diabetes.

Burge MR, Eaton RP, Schade DS.

Diabetes Technol Ther. 2016 Sep;18(9):594-603. doi: 10.1089/dia.2016.0110. Epub 2016 Sep 1. Review.

25.

Design, Synthesis, and Bioactivation of O-Glycosylated Prodrugs of the Natural Nitric Oxide Precursor N(ω)-Hydroxy-l-arginine.

Litty FA, Gudd J, Girreser U, Clement B, Schade D.

J Med Chem. 2016 Sep 8;59(17):8030-41. doi: 10.1021/acs.jmedchem.6b00810. Epub 2016 Aug 29.

PMID:
27548300
26.

Stepwise Clearance of Repressive Roadblocks Drives Cardiac Induction in Human ESCs.

Rao J, Pfeiffer MJ, Frank S, Adachi K, Piccini I, Quaranta R, Araúzo-Bravo M, Schwarz J, Schade D, Leidel S, Schöler HR, Seebohm G, Greber B.

Cell Stem Cell. 2016 Apr 7;18(4):554-6. doi: 10.1016/j.stem.2016.03.008. No abstract available.

27.

Rare complication of a common obesity procedure.

Ereifej LK, Crowell R, Schade D.

BMJ Case Rep. 2016 Feb 26;2016. pii: bcr2015214121. doi: 10.1136/bcr-2015-214121.

28.

Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.

Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Bray GA, Schade DS, Temprosa MG, White NH, Crandall JP; Diabetes Prevention Program Research Group.

J Clin Endocrinol Metab. 2016 Apr;101(4):1754-61. doi: 10.1210/jc.2015-3754. Epub 2016 Feb 22.

29.

Stepwise Clearance of Repressive Roadblocks Drives Cardiac Induction in Human ESCs.

Rao J, Pfeiffer MJ, Frank S, Adachi K, Piccini I, Quaranta R, Araúzo-Bravo M, Schwarz J, Schade D, Leidel S, Schöler HR, Seebohm G, Greber B.

Cell Stem Cell. 2016 Mar 3;18(3):341-53. doi: 10.1016/j.stem.2015.11.019. Epub 2015 Dec 31. Erratum in: Cell Stem Cell. 2016 Apr 7;18(4):554-6.

30.

Medicinal Chemistry Approaches to Heart Regeneration.

Schade D, Plowright AT.

J Med Chem. 2015 Dec 24;58(24):9451-79. doi: 10.1021/acs.jmedchem.5b00446. Epub 2015 Sep 3. Review.

PMID:
26288266
31.

Zanamivir Amidoxime- and N-Hydroxyguanidine-Based Prodrug Approaches to Tackle Poor Oral Bioavailability.

Schade D, Kotthaus J, Riebling L, Kotthaus J, Müller-Fielitz H, Raasch W, Hoffmann A, Schmidtke M, Clement B.

J Pharm Sci. 2015 Sep;104(9):3208-19. doi: 10.1002/jps.24508. Epub 2015 Jun 2.

PMID:
26037932
32.

Design, synthesis and 3D-QSAR studies of novel 1,4-dihydropyridines as TGFβ/Smad inhibitors.

Längle D, Marquardt V, Heider E, Vigante B, Duburs G, Luntena I, Flötgen D, Golz C, Strohmann C, Koch O, Schade D.

Eur J Med Chem. 2015 May 5;95:249-66. doi: 10.1016/j.ejmech.2015.03.027. Epub 2015 Mar 14.

PMID:
25817775
33.

The Effectiveness and Risks of Programming an Insulin Pump to Counteract the Dawn Phenomenon in Type 1 Diabetes.

Bouchonville M, Jaghab J, Duran-Valdez E, Schrader R, Schade D.

Endocr Pract. 2014 Aug 6:1-25. [Epub ahead of print]

PMID:
25100389
34.

Diabetes and the Affordable Care Act.

Burge MR, Schade DS.

Diabetes Technol Ther. 2014 Jul;16(7):399-413. doi: 10.1089/dia.2014.0171. Epub 2014 Jun 13.

35.

Is the masked continuous glucose monitoring system clinically useful for predicting hemoglobin A1C in type 1 diabetes?

Duran-Valdez E, Burge MR, Broderick P, Shey L, Valentine V, Schrader R, Schade DS.

Diabetes Technol Ther. 2014 May;16(5):292-7. doi: 10.1089/dia.2013.0297.

36.

Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A.

Schade D, Kotthaus J, Riebling L, Kotthaus J, Müller-Fielitz H, Raasch W, Koch O, Seidel N, Schmidtke M, Clement B.

J Med Chem. 2014 Feb 13;57(3):759-69. doi: 10.1021/jm401492x. Epub 2014 Feb 3.

PMID:
24422530
37.

Small molecules targeting in vivo tissue regeneration.

Längle D, Halver J, Rathmer B, Willems E, Schade D.

ACS Chem Biol. 2014 Jan 17;9(1):57-71. doi: 10.1021/cb4008277. Epub 2014 Jan 6. Review.

PMID:
24372447
38.

Does short-term vitamin C reduce cardiovascular risk in type 2 diabetes?

Gutierrez AD, Duran-Valdez E, Robinson I, de Serna DG, Schade DS.

Endocr Pract. 2013 Sep-Oct;19(5):785-91. doi: 10.4158/EP12431.OR.

PMID:
23757614
39.

Synthesis and SAR of b-annulated 1,4-dihydropyridines define cardiomyogenic compounds as novel inhibitors of TGFβ signaling.

Schade D, Lanier M, Willems E, Okolotowicz K, Bushway P, Wahlquist C, Gilley C, Mercola M, Cashman JR.

J Med Chem. 2012 Nov 26;55(22):9946-57. doi: 10.1021/jm301144g. Epub 2012 Nov 6.

40.

Larval competition reduces body condition in the female seed beetle, Callosobruchus maculatus.

Schade DJ, Vamosi SM.

J Insect Sci. 2012;12:35. doi: 10.1673/031.012.3501.

41.

Small molecule-mediated TGF-β type II receptor degradation promotes cardiomyogenesis in embryonic stem cells.

Willems E, Cabral-Teixeira J, Schade D, Cai W, Reeves P, Bushway PJ, Lanier M, Walsh C, Kirchhausen T, Izpisua Belmonte JC, Cashman J, Mercola M.

Cell Stem Cell. 2012 Aug 3;11(2):242-52. doi: 10.1016/j.stem.2012.04.025.

42.

Wnt inhibition correlates with human embryonic stem cell cardiomyogenesis: a structure-activity relationship study based on inhibitors for the Wnt response.

Lanier M, Schade D, Willems E, Tsuda M, Spiering S, Kalisiak J, Mercola M, Cashman JR.

J Med Chem. 2012 Jan 26;55(2):697-708. doi: 10.1021/jm2010223. Epub 2012 Jan 13.

43.

New prodrugs of the antiprotozoal drug pentamidine.

Kotthaus J, Kotthaus J, Schade D, Schwering U, Hungeling H, Müller-Fielitz H, Raasch W, Clement B.

ChemMedChem. 2011 Dec 9;6(12):2233-42. doi: 10.1002/cmdc.201100422. Epub 2011 Oct 7.

PMID:
21984033
44.

Designing modulators of dimethylarginine dimethylaminohydrolase (DDAH): a focus on selectivity over arginase.

Kotthaus J, Schade D, Kotthaus J, Clement B.

J Enzyme Inhib Med Chem. 2012 Feb;27(1):24-8. doi: 10.3109/14756366.2011.573480. Epub 2011 Jul 8.

PMID:
21740101
45.

Prodrug design for the potent cardiovascular agent Nω-hydroxy-L-arginine (NOHA): synthetic approaches and physicochemical characterization.

Schade D, Kotthaus J, Klein N, Kotthaus J, Clement B.

Org Biomol Chem. 2011 Jul 21;9(14):5249-59. doi: 10.1039/c0ob01117g. Epub 2011 May 31.

PMID:
21625725
46.

Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes.

Wessells H, Penson DF, Cleary P, Rutledge BN, Lachin JM, McVary KT, Schade DS, Sarma AV; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group.

J Urol. 2011 May;185(5):1828-34. doi: 10.1016/j.juro.2010.12.098. Epub 2011 Mar 21.

47.

Synthesis and biological evaluation of L-valine-amidoximeesters as double prodrugs of amidines.

Kotthaus J, Hungeling H, Reeh C, Kotthaus J, Schade D, Wein S, Wolffram S, Clement B.

Bioorg Med Chem. 2011 Mar 15;19(6):1907-14. doi: 10.1016/j.bmc.2011.01.066. Epub 2011 Feb 3.

PMID:
21345682
48.

Reduction of N(ω)-hydroxy-L-arginine by the mitochondrial amidoxime reducing component (mARC).

Kotthaus J, Wahl B, Havemeyer A, Kotthaus J, Schade D, Garbe-Schönberg D, Mendel R, Bittner F, Clement B.

Biochem J. 2011 Jan 15;433(2):383-91. doi: 10.1042/BJ20100960.

PMID:
21029045
49.

Modulating the NO generating system from a medicinal chemistry perspective: current trends and therapeutic options in cardiovascular disease.

Schade D, Kotthaus J, Clement B.

Pharmacol Ther. 2010 Jun;126(3):279-300. doi: 10.1016/j.pharmthera.2010.02.005. Epub 2010 Mar 10. Review.

PMID:
20226211
50.

Metabolism and distribution of two highly potent and selective peptidomimetic inhibitors of matriptase.

Kotthaus J, Steinmetzer T, Kotthaus J, Schade D, van de Locht A, Clement B.

Xenobiotica. 2010 Feb;40(2):93-101. doi: 10.3109/00498250903402266.

PMID:
20028195

Supplemental Content

Loading ...
Support Center